Psychiatric Comorbidity of Gender Identity Disorders: A Survey Among Dutch Psychiatrists

Joost à Campo, M.D.
Henk Nijman, Ph.D.
H. Merckelbach, Ph.D.
Catharine Evers, M.Sc.

Objective: In the Netherlands, it is considered good medical practice to offer patients with gender identity disorder the option to undergo hormonal and surgical sex reassignment therapy. A liberalization of treatment guidelines now allows for such treatment to be started at puberty or prepuberty. The question arises as to what extent gender identity disorder can be reliably distinguished from a cross-gender identification that is secondary to other psychiatric disorders.

Method: The authors sent survey questionnaires to 382 board-certified Dutch psychiatrists regarding their experiences with diagnosing and treating patients with gender identity disorder.

Results: One hundred eighty-six psychiatrists responded to the survey. These respondents reported on 584 patients with cross-gender identification. In 225 patients (39%), gender identity disorder was regarded as the primary diagnosis. For the remaining 359 patients (61%), cross-gender identification was comorbid with other psychiatric disorders. In 270 (75%) of these 359 patients, cross-gender identification was interpreted as an epiphenomenon of other psychiatric illnesses, notably personality, mood, dissociative, and psychotic disorders.

Conclusions: These data suggest that there is little consensus, at least among Dutch psychiatrists, about diagnostic features of gender identity disorder or about the minimum age at which sex reassignment therapy is a safe option. Therapy options proposed to patients with gender identity disorder appear to depend on personal preferences of psychiatrists. These results underline the need for more specific diagnostic rules in this area.

According to DSM-IV, gender identity disorder is characterized by a strong and persistent cross-gender identification and persistent discomfort with one’s own sex. With an estimated worldwide lifetime prevalence of 0.001%–0.002%, gender identity disorder is rare (1). However, the prevalence of gender identity disorder appears to be higher in the Netherlands. Here, male-to-female gender identity disorder is found in about 1 per 12,000 inhabitants and female-to-male gender identity disorder is seen in 1 per 30,000 (2).

About two-thirds of the patients referred to Dutch gender clinics are given the opportunity to undergo hormonal therapy; many are also offered surgical sex reassignment therapy. In line with the liberal tradition of the Netherlands, there appears to be no serious opposition against this invasive treatment for patients with gender identity disorder. Dutch research suggests that patients with gender identity disorder generally benefit from sex reassignment therapy (3), although studies from other countries (4–6) report somewhat higher percentages of patients regretting their sex reassignment therapy (i.e., about 10%–20%).

Recently, treatment guidelines for gender identity disorder have been further liberalized in the Netherlands; the new guidelines allow patients in puberty or prepuberty to apply for sex reassignment therapy. During the first phase of this therapy, patients receive hormones blocking their normal sexual maturation (7). At age 16, actual sex reassignment starts by administration of hormones of the desired sex (i.e., estrogens for male-to-female and androgens for female-to-male patients). Each year, about 10 youngsters receive this treatment regimen (7). However, a potential problem with lowering the age for sex reassignment procedures is that it may increase the risk of false positive diagnoses.

A case in point is schizophrenia, a condition that cannot be diagnosed with reasonable certainty until early adulthood. DSM-IV states that “delusions of belonging to the other sex” (p. 537) are rarely seen in schizophrenia, but this claim is difficult to reconcile with studies showing that about 25% of patients with schizophrenia experience cross-gender identification at some point in their life (8–11). In line with this, for a diagnosis of gender identity disorder (previously termed “transsexualism”), DSM-III required that the symptoms were “not due to another mental disorder, such as Schizophrenia” (p. 264). Later editions of DSM have dropped this exclusion criterion. However, when it comes to diagnostic criteria for other disorders involving body image (e.g., body dysmorphic disorder), DSM-IV emphasizes that concomitant psychiatric dis-
orders have to be ruled out. DSM-IV acknowledges that omission of this exclusion criterion creates the possibility that “Schizophrenia and severe Gender Identity Disorder may coexist” in the same patient but adds that such comorbidity is unlikely (p. 537).

That the diagnostic differentiation between gender identity disorder and schizophrenia might sometimes be difficult is illustrated by a patient who was referred to one of us (J.Á.C.) (12). For a period of 6 years, this patient had been treated with hormones in a gender reassignment center. While being scheduled for gender reassignment surgery, the patient was referred to our psychiatric facility because of a psychotic decompensation. He was diagnosed as suffering from schizophrenia of the paranoid type, and when he was given neuroleptic medication his psychotic symptoms decreased and his feelings of being a woman in a man's body disappeared. In retrospect, it appears that this patient interpreted his cross-gender confusion as part of his delusional thinking. Although he is now doing well on a regimen of antipsychotic drugs and lives in the community, he deeply regrets the hormonal treatment and suffers from its irreversible side effects (e.g., atrophy of the genitals and female breasts).

This case suggests that cross-gender delusions in patients with schizophrenia may mimic the persistent and stable cross-gender identification seen in patients with gender identity disorder. The psychiatric literature offers several anecdotal reports of cases in which cross-gender identification disappeared when patients were treated with antipsychotic medication (12–17). There are also case descriptions of patients whose cross-gender identification returned after antipsychotic medication was stopped (18). Finally, there are reports of remission of gender identity disorder in nonpsychotic, nonmedicated adult patients (19). The supporting text for the DSM-IV gender identity disorder criteria assumes that a patient with genuine gender identity disorder “feels like a member of the other sex rather than truly believes that he or she is a member of the other sex” (p. 537). In many cases, this clinical heuristic might be useful, but the example cited here suggests that it sometimes fails.

When patients with gender identity disorder suffer from severe comorbid psychopathology, it may be difficult for psychiatrists to decide which diagnosis should have a primary status. It is obvious that, in such cases, any decision has far-reaching consequences for the type of treatment selected and for the well-being of the patients involved. How often are psychiatrists confronted with cross-gender identification cases in which diagnostic complications arise? To address this issue, we assessed current opinions about comorbidity and treatment of gender identity disorder in a national sample of board-certified psychiatrists.

Method

From the records of the Dutch Psychiatric Association, we randomly selected 382 psychiatrists. In July 2000, these psychiatrists were sent an 11-item questionnaire that asked them whether they had ever treated patients who experienced cross-gender confusion (Appendix 1). When they said they had, psychiatrists were asked to specify, for each case they had treated, whether they judged gender identity disorder to be the primary diagnosis or the cross-gender confusion was interpreted and treated as secondary to other psychiatric conditions. Additionally, several questions addressing the psychiatrists’ opinions about diagnosing and treating gender identity disorder were asked. The final item invited respondents to comment freely on the issue.

Results

Of the 382 psychiatrists, 186 (49%) completed and returned the questionnaire before the deadline of September 29, 2000. Respondents had been working as psychiatrists for a mean of 13.9 years (SD=7.4, range=0.5–31.0).

Experiences With Cross-Gender Confusion and Gender Identity Disorder

A large majority of the respondents (76% [N=142]) had treated cross-gender confused patients at least once. The total number of patients treated varied from 0 to 50 per psychiatrist. As anticipated, there was a modest but significant correlation between years of working experience and number of patients treated (Pearson’s r=0.15, N=186, p<0.05). In total, the 186 respondents reported about 584 patients suffering from cross-gender confusion. When this rate is generalized to the entire population of Dutch psychiatrists, it would mean that Dutch psychiatrists are consulted every 4.5 years by a patient who experiences cross-gender confusion.

In 225 (39%) of the 584 reported cases, gender identity disorder was regarded as the primary diagnosis. For the remaining 359 patients (61%), cross-gender confusion occurred along with other psychiatric disorders, and in 270 (75%) of these 359 cases, it was interpreted as secondary to other psychiatric illnesses.

Nature of Psychiatric Comorbidity

One hundred twenty-nine psychiatrists specified psychiatric comorbidity for their patients with gender identity disorder. Comorbid personality disorders were reported by 102 (79%) of the 129 psychiatrists, major mood disorders by 34 (26%), dissociative disorders by 34 (26%), and psychotic disorders by 31 (24%).

We asked psychiatrists whether they agreed with the DSM-IV heuristic not to rule out other disorders in cases where a gender identity disorder diagnosis is considered. One hundred seventy-seven of the 186 respondents answered this question; 38 (21%) of these respondents indicated that they were not able to make up their mind about this issue. Of the 139 psychiatrists who did express an opinion, 78 (56%) considered this heuristic not to be wise.
Treatment

Of the 142 psychiatrists who had treated patients with cross-gender confusion, 40 (28%) had referred patients to specialized gender clinics for further treatment at least once. These 40 psychiatrists had referred 73 patients (range=1–15) to sex reassignment therapy facilities. The large majority of the referring psychiatrists (75% [N=30]) had referred only one patient to a gender clinic. Thus, the remaining group of 10 psychiatrists was responsible for the majority of referrals to gender clinics (i.e., 43 [59%] of the 73 referrals).

Only 95 (51%) of the 186 respondents were willing to specify an appropriate age for starting gender reassignment therapy. One psychiatrist said that gender reassignment should not be considered until the patient reaches the age of 85. After exclusion of this curious outlier, the mean recommended starting age was 18.7 years (SD=3.9, range=10–25).

Discussion

A majority of Dutch psychiatrists reported that they had encountered patients with cross-gender confusion at least once. This finding should be interpreted with caution because of limitations inherent to surveys. Although psychiatrists were randomly selected and the response rate was acceptable (49%), it may be that psychiatrists who did not have any experience with such patients were less inclined to return the questionnaire. Apart from that, we cannot rule out that the reported patient cases included duplications: some patients may have been treated by more than one of the responding psychiatrists.

In spite of these limitations, the conclusion seems warranted that at some point in their career, most Dutch psychiatrists will be consulted by a patient suffering from cross-gender confusion. Therefore, it is important that there be consensus about the diagnostic procedures and treatment options that should be considered for such patients. Our results, however, suggest that opinions differ as to the type of treatment that should be considered first in these cases. A small number of psychiatrists seem to refer such patients to specialized sex reassignment therapy centers on a regular basis, but others never seem to recommend this treatment route. It appears that the therapy options proposed to patients with gender identity disorder depend heavily on the personal preferences of psychiatrists. Thus, one respondent said he had referred 15 patients to a gender clinic, but another remarked that “the scalpel should not be used to reconcile fantasy with reality.” The view of this latter respondent corresponds to that of McHugh (20), who noted that it is hard to understand how the belief of a male patient “that he is a woman trapped in a man’s body differs from the feelings of a patient with anorexia nervosa that she is obese despite her emaciated, cachectic state. We don’t do liposuction on anorexics. So why amputate the genitals of these patients?” (p. 111).

Opinions also differed with regard to diagnostic routines and the minimum age for sex reassignment therapy to be a safe treatment. Almost half of the respondents were not willing to specify a minimum starting age for such treatment. The average minimum age specified by respondents who were willing to answer this question was well above the legally permissible age for this procedure in the Netherlands.

Personality, mood, dissociative, and psychotic disorders were the most often reported psychiatric conditions comorbid with gender identity disorder. In about half of the cases that were reported, cross-gender confusion was regarded as an epiphenomenon of other illnesses. Although psychiatrists probably see a self-selected group of patients with cross-gender confusion (those with psychiatric problems would be more likely to visit a psychiatrist), these results underline the need for education of general physicians about psychiatric comorbidity of cross-gender identification.

Our findings also underline the need for articulated diagnostic rules in this area. A nontrivial proportion of our respondents felt that the current DSM-IV gender identity disorder criteria are not strict enough. These respondents indicated that other psychiatric disorders that may explain the cross-gender symptoms should be ruled out before considering a diagnosis of gender identity disorder. There is evidence suggesting that persistent cross-gender identification may occur in psychotic patients. In such cases, the cross-gender confusion appears to be entirely attributable to the misperception of reality that is typical for psychotic disorders (12–18).

Our results, together with anecdotal reports about gender identity disorder misdiagnoses, indicate that it may be fruitful to consider reinstatement of an exclusion criterion that cross-gender symptoms should not be attributable to other psychiatric disorders such as schizophrenia. The current DSM criteria allow for a situation in which gender identity disorder and schizophrenia “may coexist” in a patient (DSM-IV, p. 537). One of our respondents said, “When a patient has an acute psychotic episode, I wouldn’t dare to diagnose gender identity disorder.”

The fact that psychosis is mentioned relatively often as a comorbid problem of gender identity disorder also calls for a very careful evaluation of the benefits and risks involved in lowering the starting age for sex-adjustment treatment. The more florid symptoms of psychotic disorders generally do not emerge until adolescence and early adulthood. Confusion about one’s identity, body image aberrations, and the wish to drastically change one’s appearance (e.g., references 21, 22), however, may become manifest before actual psychotic breakdown occurs, as was the case in our hormonally treated psychotic patient (12). Discussions about the proper age for starting sex reassignment therapy should take into account the far-
reaching consequences of misclassifying psychotic patients’ cross-gender confusion as gender identity disorder. Thus, in order to assess reliably the nature of the expressed desire to change gender, it may be necessary to wait until early adulthood before sex reassignment therapy becomes a safe option. We feel that independent committees that monitor and evaluate referrals to sex reassignment therapies would be of benefit in this area. Psychiatrists should be well represented on such committees.

APPENDIX 1. Cross-Gender Treatment Survey Questions

1. How many years have you been working as a psychiatrist? _____ years
2. In your career as a psychiatrist, how many times have you dealt with patients with cross-gender confusion? _____ times
3. For how many of these patients did you establish gender identity disorder as a primary diagnosis? _____ patients
4. For how many of these patients did you judge the cross-gender identification to be secondary to other DSM-IV diagnoses? _____ patients
5. In how many of your patients with gender identity disorder did comorbid psychiatric disorders exist? _____ patients
6. If you have experience with patients suffering from gender identity disorder in combination with comorbid psychiatric disorders, what comorbid disorders were those? ________________________________

7. Did you ever refer a patient to a gender reassignment center? _____ Yes, _____ times
8. Were these referred patients suffering from comorbid psychiatric disorders as mentioned in question 5? _____ Yes, _____ times
9. According to the DSM-IV gender identity disorder criteria, psychiatric disorders such as schizophrenia do not have to be ruled out to establish a diagnosis of gender identity disorder. Do you agree with this procedure? _____ Yes, _____ times
10. What in your opinion is an appropriate age to start sex reassignment therapy? _____ years
11. Do you wish to comment further on this issue? __________________________________________________

Received May 29, 2002; revision received Oct. 2, 2002; accepted Jan. 22, 2003. From Mondriaan Zorggroep Hospital; Forensic Psychiatry Hospital Kijvelanden, Poortugaal, the Netherlands; the Department of Experimental Psychology, Maastricht University, Maastricht, the Netherlands; and the Department of Social Psychology of the University of Amsterdam, the Netherlands. Address reprint requests to Dr. à Campo, Mondriaan Zorggroep Hospital, P.O. Box 4436, 6401 CX Heerlen, the Netherlands; camrep@planet.nl (e-mail).

References